Identifying new small molecule anti-invasive compounds for glioma treatment

Cell Cycle

Volumn 12, Issue 14, 2013, Pages 2200-2209

  Munson, Jennifer ^a   Bonner, Michael ^b   Fried, Levi ^b   Hofmekler, Jonathan ^b   Arbiser, Jack ^b   Bellamkonda, Ravi ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Drug screen; Glioma; Invasion; NADPH oxidase

Indexed keywords

2 [N (4 METHOXYSULFONYL)(3 PYRIDINYLMETHYL)AMINO] 3 METHYLBUTYROHYDROXAMIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEBBISTATIN; CILENGITIDE; CYTOCHALASIN; GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JASPAMIDE; MARIMASTAT; MMI 166; PACLITAXEL; PF 573 228; PHALLOIDIN; PRINOMASTAT; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL ADHESION; CYTOREDUCTIVE SURGERY; CYTOSKELETON; DRUG BIOAVAILABILITY; DRUG SCREENING; ENZYME DEGRADATION; GLIOBLASTOMA; GLIOMA; HUMAN; INDUCTION CHEMOTHERAPY; NONHUMAN; TARGET CELL DESTRUCTION; TUMOR INVASION;

EID: 84880432356     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25334     Document Type: Article

References (109)

1. National Cancer Institute Brain Tumor Study in Adults: Fact 2000
2. Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010; 17:417-21; PMID:20167494; http://dx.doi.org/10.1016/j.jocn.2009.09.004
3. Mikkelsen T. (1998) Brain tumor invasion: biological, clinical, and therapeutic considerations (Wiley- Liss, New York):464.
4. Price SJ, Jena R, Burnet NG, Hutchinson PJ, Dean AF, Peña A, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol 2006; 27:1969-74; PMID:17032877 (Pubitemid 44556519)
5. Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 2010; 112:10-7; PMID:19361270; http://dx.doi.org/10.3171/2008.10.JNS08608
6. Dinnes J, Cave C, Huang S, Milne R. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 2002; 86:501-5; PMID:11870527; http://dx.doi.org/10.1038/sj.bjc. 6600135 (Pubitemid 34185082)
7. Nabors LB, Fiveash J. Treatment of adults with recurrent malignant glioma. Expert Rev Neurother 2005; 5:509-14; PMID:16026234; http://dx.doi.org/ 10.1586/14737175.5.4.509 (Pubitemid 41021057)
8. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330 (Pubitemid 40349501)
9. Jain RK. Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1999; 1:241-63; PMID:11701489; http://dx.doi.org/10.1146/ annurev.bioeng.1.1.241 (Pubitemid 129740012)
10. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001; 46:149-68; PMID:11259838; http://dx.doi.org/10.1016/S0169- 409X(00)00131-9
11. Gliemroth J, Feyerabend T, Gerlach C, Arnold H, Terzis AJ. Proliferation, migration, and invasion of human glioma cells exposed to fractionated radiotherapy in vitro. Neurosurg Rev 2003; 26:198-205; PMID:12845549; http://dx.doi.org/10.1007/s10143-003-0258-9 (Pubitemid 36835039)
12. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M, et al. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 2006; 76:227-37; PMID:16200346; http://dx.doi.org/10.1007/s11060-005-6499-4
13. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 2001; 61:2744-50; PMID:11289157 (Pubitemid 32685864)
14. Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M. Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 2002; 62:1915-9; PMID:11912174 (Pubitemid 34408522)
15. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005; 5:516-25; PMID:15965493; http://dx.doi.org/10.1038/nrc1650 (Pubitemid 40942828)
16. Madani I, De Neve W, Mareel M. Does ionizing radiation stimulate cancer invasion and metastasis? Bull Cancer 2008; 95:292-300; PMID:18390409 (Pubitemid 351528766)
17. Barcellos-Hoff MH. The potential inf luence of radiation-induced microenvironments in neoplastic progression. J Mammary Gland Biol Neoplasia 1998; 3:165-75; PMID:10819525; http://dx.doi.org/10.1023/A:1018794806635 (Pubitemid 128513228)
18. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 2000; 60:1254-60; PMID:10728684 (Pubitemid 30151992)
19. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004; 64:3215-22; PMID:15126362; http://dx.doi.org/10.1158/0008-5472.CAN-03-2464 (Pubitemid 38581425)
20. Nakamura JL, Haas-Kogan DA, Pieper RO. Glioma invasiveness responds variably to irradiation in a co-culture model. Int J Radiat Oncol Biol Phys 2007; 69:880-6; PMID:17889268; http://dx.doi.org/10.1016/j.ijrobp.2007.06.052 (Pubitemid 47418417)
21. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, et al. Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 2006; 66:8511-9; PMID:16951163; http://dx.doi.org/10.1158/0008-5472.CAN-05-4340
22. Badiga AV, Chetty C, Kesanakurti D, Are D, Gujrati M, Klopfenstein JD, et al. MMP-2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS One 2011; 6:e20614; PMID:21698233; http://dx.doi.org/10.1371/journal.pone. 0020614
23. Argyriou AA, Giannopoulou E, Kalofonos HP. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology 2009; 77:1-11; PMID:19439998; http://dx.doi.org/10.1159/000218165
24. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 2003; 88:169-77; PMID:14531575
25. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008; 105:9343-8; PMID:18607000; http://dx.doi.org/10. 1073/pnas.0803728105
26. Miller KD, Soule SE, Calley C, Emerson RE, Hutchins GD, Kopecky K, et al. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 2005; 89:187-97; PMID:15692762; http://dx.doi.org/10.1007/s10549-004- 2044-y (Pubitemid 40249053)
27. Gömöri E, Fülöp Z, Mészáros I, Dóczi T, Matolcsy A. Microsatellite analysis of primary and recurrent glial tumors suggests different modalities of clonal evolution of tumor cells. J Neuropathol Exp Neurol 2002; 61:396-402; PMID:12025942 (Pubitemid 34533670)
28. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, et al. Cancer cell adaptation to chemotherapy. BMC Cancer 2005; 5:78; PMID:16026610; http://dx.doi.org/10.1186/1471-2407-5-78
29. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006; 13:1238-41; PMID:16456578; http://dx.doi.org/10.1038/sj.cdd.4401872 (Pubitemid 43905604)
30. Borovski T, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res 2011; 71:634-9; PMID:21266356; http://dx.doi.org/10.1158/0008-5472.CAN-10-3220
31. Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes- Santiago N, et al. Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget 2010; 1:700-9; PMID:21321379
32. Nakano A, Tani E, Miyazaki K, Yamamoto Y, Furuyama J. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995; 83:298-307; PMID:7616276; http://dx.doi.org/10.3171/jns.1995. 83.2.0298
33. Chintala SK, Rao JK. Invasion of human glioma: role of extracellular matrix proteins. Front Biosci 1996; 1:d324-39; PMID:9159237
34. Rubenstein BM, Kaufman LJ. The role of extracellular matrix in glioma invasion: a cellular Potts model approach. Biophys J 2008; 95:5661-80; PMID:18835895; http://dx.doi.org/10.1529/biophysj.108.140624
35. Uhm JH, Dooley NP, Villemure JG, Yong VW. Mechanisms of glioma invasion: role of matrixmetalloproteinases. Can J Neurol Sci 1997; 24:3-15; PMID:9043741 (Pubitemid 27105308)
36. Le DM, Besson A, Fogg DK, Choi KS, Waisman DM, Goodyer CG, et al. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase- type plasminogen activator-plasmin cascade. J Neurosci 2003; 23:4034-43; PMID:12764090 (Pubitemid 36958422)
37. Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, et al. Randomized, double- blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006; 78:295-302; PMID:16636750; http://dx.doi.org/10.1007/s11060-005-9098-5 (Pubitemid 44018824)
38. Sorbera LA, Castaner J. Prinomastat: oncolytic, matrix metalloproteinase inhibitor. Drugs Future 2000; 25:150-8; http://dx.doi.org/10.1358/dof.2000.025. 02.567506 (Pubitemid 30182773)
39. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001; 7:1912-22; PMID:11448904 (Pubitemid 32994825)
40. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295:2387-92; PMID:11923519; http://dx.doi.org/10.1126/science. 1067100 (Pubitemid 34270240)
41. Nakabayashi H, Yawata T, Shimizu K. Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells. BMC Cancer 2010; 10:339; PMID:20587068; http://dx.doi.org/10.1186/1471-2407-10-339
42. Jin SG, Jeong YI, Jung S, Ryu HH, Jin YH, Kim IY. The effect of hyaluronic Acid on the invasiveness of malignant glioma cells: comparison of invasion potential at hyaluronic Acid hydrogel and matrigel. J Korean Neurosurg Soc 2009; 46:472-8; PMID:20041058; http://dx.doi.org/10.3340/jkns.2009.46.5.472
43. Demchik LL, Sameni M, Nelson K, Mikkelsen T, Sloane BF. Cathepsin B and glioma invasion. Int J Dev Neurosci 1999; 17:483-94; PMID:10571410; http://dx.doi.org/10.1016/S0736-5748(99)00011-8 (Pubitemid 29421835)
44. Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004; 36:1046-69; PMID:15094120; http://dx.doi.org/10.1016/ j.biocel.2004.01.013 (Pubitemid 38501557)
45. Goldbrunner RH, Bernstein JJ, Tonn JC. ECM-mediated glioma cell invasion. Microsc Res Tech 1998; 43:250-7; PMID:9840803; http://dx.doi.org/10.1002/(SICI) 1097-0029(19981101)43:3 3.0.CO;2-C (Pubitemid 28524648)
46. Goldbrunner RH, Bernstein JJ, Tonn JC. Cellextracellular matrix interaction in glioma invasion. Acta Neurochir (Wien) 1999; 141(discussion 304-295):295-305, discussion 304-5; PMID:10214487; http://dx.doi.org/10.1007/ s007010050301 (Pubitemid 29137544)
47. Gingras MC, Roussel E, Bruner JM, Branch CD, Moser RP. Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue. J Neuroimmunol 1995; 57:143-53; PMID:7535788; http://dx.doi.org/10.1016/0165-5728(94)00178-Q
48. Maurer GD, Tritschler I, Adams B, Tabatabai G, Wick W, Stupp R, et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro Oncol 2009; 11:747-56; PMID:19221171; http://dx.doi.org/10.1215/15228517-2009-012
49. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al. Randomized phase II study of cilengitide, an integrin-targeting arginineglycine- aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26:5610-7; PMID:18981465; http://dx.doi.org/10.1200/JCO.2008. 16.7510
50. Giese A, Laube B, Zapf S, Mangold U, Westphal M. Glioma cell adhesion and migration on human brain sections. Anticancer Res 1998; 18(4A):2435-47; PMID:9703890 (Pubitemid 28386531)
51. Kaczarek E, Zapf S, Bouterfa H, Tonn JC, Westphal M, Giese A. Dissecting glioma invasion: interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype. Int J Dev Neurosci 1999; 17:625-41; PMID:10571423; http://dx.doi.org/10.1016/S0736-5748(99)00047-7 (Pubitemid 29421848)
52. Gimona M. The microfilament system in the formation of invasive adhesions. Semin Cancer Biol 2008; 18:23-34; PMID:17936638; http://dx.doi.org/ 10.1016/j.semcancer.2007.08.005 (Pubitemid 350266371)
53. Hao H, Naomoto Y, Bao X, Watanabe N, Sakurama K, Noma K, et al. Focal adhesion kinase as potential target for cancer therapy (Review). Oncol Rep 2009; 22:973-9; PMID:19787209
54. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008; 14:627-32; PMID:18245520; http://dx.doi.org/10.1158/1078-0432.CCR-07- 2220 (Pubitemid 351231140)
55. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007; 282:14845-52; PMID:17395594; http://dx.doi.org/10.1074/jbc. M606695200 (Pubitemid 47093369)
56. Merzak A, Koocheckpour S, Pilkington GJ. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res 1994; 54:3988-92; PMID:7518347 (Pubitemid 24258098)
57. Tysnes BB, Mahesparan R. Biological mechanisms of glioma invasion and potential therapeutic targets. J Neurooncol 2001; 53:129-47; PMID:11716066; http://dx.doi.org/10.1023/A:1012249216117 (Pubitemid 33036822)
58. Yamaguchi H, Oikawa T. Membrane lipids in invadopodia and podosomes: key structures for cancer invasion and metastasis. Oncotarget 2010; 1:320-8; PMID:21307399
59. Fenteany G, Zhu S. Small-molecule inhibitors of actin dynamics and cell motility. Curr Top Med Chem 2003; 3:593-616; PMID:12570855; http://dx.doi.org/ 10.2174/1568026033452348
60. Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, et al. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 1997; 75:1744-52; PMID:9192976; http://dx.doi.org/10.1038/bjc.1997.298 (Pubitemid 27230698)
61. Tonn JC, Haugland HK, Saraste J, Roosen K, Laerum OD. Differential effects of vincristine and phenytoin on the proliferation, migration, and invasion of human glioma cell lines. J Neurosurg 1995; 82:1035-43; PMID:7539063; http://dx.doi.org/10.3171/jns.1995.82.6.1035
62. Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS, Canoll P. The role of myosin II in glioma invasion of the brain. Mol Biol Cell 2008; 19:3357-68; PMID:18495866; http://dx.doi.org/10.1091/mbc. E08-03-0319
63. Ivkovic S, Beadle C, Noticewala S, Massey SC, Swanson KR, Toro LN, et al. Direct inhibition of myosin II effectively blocks glioma invasion in the presence of multiple motogens. Mol Biol Cell 2012; 23:533-42; PMID:22219380; http://dx.doi.org/10.1091/mbc.E11-01-0039
64. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci 2005; 96:379-86; PMID:16053508; http://dx.doi.org/10.1111/j.1349-7006.2005.00062.x (Pubitemid 41179738)
65. De Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 2010; 12:304-16; PMID:20167819; http://dx.doi.org/10.1093/neuonc/nop068
66. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2:833-49; PMID:22064833
67. Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 2007; 99:1583-93; PMID:17971532; http://dx.doi.org/10.1093/jnci/djm187 (Pubitemid 351767231)
68. Nico B, Ribatti D. Aquaporins in tumor growth and angiogenesis. Cancer Lett 2010; 294:135-8; PMID:20199845; http://dx.doi.org/10.1016/j.canlet.2010.02. 005
69. Molenaar RJ. Ion channels in glioblastoma. ISRN Neurol 2011; 2011:590249; PMID:22389824; http://dx.doi.org/10.5402/2011/590249
70. Papadopoulos MC, Saadoun S, Verkman AS. Aquaporins and cell migration. Pflugers Arch 2008; 456:693-700; PMID:17968585; http://dx.doi.org/10.1007/ s00424-007-0357-5 (Pubitemid 351692135)
71. Ding T, Gu F, Fu L, Ma YJ. Aquaporin-4 in glioma invasion and an analysis of molecular mechanisms. J Clin Neurosci 2010; 17:1359-61; PMID:20685122; http://dx.doi.org/10.1016/j.jocn.2010.02.014
72. Hayashi Y, Edwards NA, Proescholdt MA, Oldfield EH, Merrill MJ. Regulation and function of aquaporin-1 in glioma cells. Neoplasia 2007; 9:777-87; PMID:17898873; http://dx.doi.org/10.1593/neo.07454 (Pubitemid 47523239)
73. Patterson LH, McKeown SR. AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 2000; 83:1589-93; PMID:11104551; http://dx.doi.org/10.1054/bjoc.2000.1564 (Pubitemid 32001698)
74. Patterson LH, McKeown SR, Ruparelia K, Double JA, Bibby MC, Cole S, et al. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 2000; 82:1984-90; PMID:10864207 (Pubitemid 30326460)
75. Soroceanu L, Manning TJ Jr., Sontheimer H. Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. J Neurosci 1999; 19:5942-54; PMID:10407033 (Pubitemid 29327929)
76. McFerrin MB, Sontheimer H. A role for ion channels in glioma cell invasion. Neuron Glia Biol 2006; 2:39-49; PMID:16520829; http://dx.doi.org/10. 1017/S1740925X06000044 (Pubitemid 43248063)
77. Zagzag D, Esencay M, Mendez O, Yee H, Smirnova I, Huang Y, et al. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol 2008; 173:545-60; PMID:18599607; http://dx.doi.org/10.2353/ajpath.2008.071197
78. Sciumè G, Santoni A, Bernardini G. Chemokines and glioma: invasion and more. J Neuroimmunol 2010; 224:8-12; PMID:20656128; http://dx.doi.org/10. 1016/j.jneuroim.2010.05.019
79. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003; 100:13513-8; PMID:14595012; http://dx.doi.org/10.1073/pnas.2235846100 (Pubitemid 37444773)
80. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2:581-7; PMID:12815382; http://dx.doi.org/10.1038/nrd1134 (Pubitemid 37361749)
81. De Clercq E. Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100. Mini Rev Med Chem 2005; 5:805-24; PMID:16178723; http://dx.doi.org/10.2174/1389557054867075 (Pubitemid 41167497)
82. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006; 656:529-39; http://dx.doi.org/10.1097/00005072-200606000-00001 (Pubitemid 44288937)
83. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027
84. Méndez O, Zavadil J, Esencay M, Lukyanov Y, Santovasi D, Wang SC, et al. Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 2010; 9:133; PMID:20515450; http://dx.doi.org/10.1186/1476-4598-9-133
85. Chau NM, Rogers P, Aherne W, Carroll V, Collins I, McDonald E, et al. Identification of novel smallmolecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors. Cancer Res 2005; 65:4918-28; PMID:15930314; http://dx.doi.org/ 10.1158/0008-5472.CAN-04-4453 (Pubitemid 40740832)
86. Kong D, Park EJ, Stephen AG, Calvani M, Cardellina JH, Monks A, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNAbinding activity. Cancer Res 2005; 65:9047-55; PMID:16204079; http://dx.doi.org/10. 1158/0008-5472.CAN-05-1235 (Pubitemid 41377397)
87. Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol 2007; 74:191-201; PMID:17498666; http://dx.doi.org/10.1016/j.bcp.2007.04.003 (Pubitemid 46890812)
88. Shankar S, Ganapathy S, Hingorani SR, Srivastava RK. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 2008; 13:440-52; PMID:17981559; http://dx.doi.org/10.2741/2691 (Pubitemid 351599756)
89. Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N, et al. Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 2003; 196:394-402; PMID:12811834; http://dx.doi.org/10.1002/jcp.10306 (Pubitemid 36775888)
90. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem 2003; 278:35501-7; PMID:12816951; http://dx.doi.org/10.1074/jbc.M302967200 (Pubitemid 37102321)
91. Wolf I, O'Kelly J, Wakimoto N, Nguyen A, Amblard F, Karlan BY, et al. Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int J Oncol 2007; 30:1529-37; PMID:17487375
92. Shigemura K, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, et al. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer 2007; 109:1279-89; PMID:17326044; http://dx.doi.org/10.1002/cncr.22551 (Pubitemid 46466554)
93. Ahn KS, Sethi G, Shishodia S, Sung B, Arbiser JL, Aggarwal BB. Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res 2006; 4:621-33; PMID:16966432; http://dx.doi.org/10.1158/1541-7786.MCR-06-0076 (Pubitemid 44497215)
94. Rayet B, Gélinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18:6938-47; PMID:10602468; http://dx.doi.org/10.1038/sj. onc.1203221
95. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431:461-6; PMID:15329734; http://dx.doi.org/10.1038/nature02924 (Pubitemid 39329586)
96. Tertil M, Jozkowicz A, Dulak J. Oxidative stress in tumor angiogenesis-therapeutic targets. Curr Pharm Des 2010; 16:3877-94; PMID:21158725; http://dx.doi.org/10.2174/138161210794454969
97. Cooney RV, Pung A, Harwood PJ, Boynton AL, Zhang LX, Hossain MZ, et al. Inhibition of cellular transformation by triphenylmethane: a novel chemopreventive agent. Carcinogenesis 1992; 13:1107-12; PMID:1638675; http://dx.doi.org/10.1093/carcin/13.7.1107
98. Salhia B, Rutten F, Nakada M, Beaudry C, Berens M, Kwan A, et al. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1. Cancer Res 2005; 65:8792-800; PMID:16204049; http://dx.doi.org/10.1158/0008-5472.CAN-05-0160 (Pubitemid 41377367)
99. Salhia B, Tran NL, Symons M, Winkles JA, Rutka JT, Berens ME. Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn 2006; 6:613-26; PMID:16824034; http://dx.doi.org/10.1586/14737159.6.4.613 (Pubitemid 44179946)
100. Diaz B, Shani G, Pass I, Anderson D, Quintavalle M, Courtneidge SA. Tks5-dependent, nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. Sci Signal 2009; 2:ra53; PMID:19755709; http://dx.doi.org/10.1126/scisignal. 2000368
101. Munson JM, Fried L, Rowson SA, Bonner MY, Karumbaiah L, Diaz B, et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med 2012; 4:27ra36; PMID:22461640; http://dx.doi.org/10.1126/scitranslmed.3003016
102. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget 2011; 2:1203-17; PMID:22203497
103. Nakamura T, Saito R, Sugiyama S, Sonoda Y, Kumabe T, Tominaga T. Local convection-enhanced delivery of chemotherapeutic agent transiently opens blood-brain barrier and improves efficacy of systemic chemotherapy in intracranial xenograft tumor model. Cancer Lett 2011; 310:77-83; PMID:21763069; http://dx.doi.org/10.1016/j.canlet.2011.06.018
104. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, et al. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 1994; 33:779-86; PMID:7993646; http://dx.doi.org/10.3109/02841869409083948 (Pubitemid 24380309)
105. Siegal T, Horowitz A, Gabizon A. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 1995; 83:1029-37; PMID:7490617; http://dx.doi.org/10.3171/jns.1995.83.6.1029 (Pubitemid 26048143)
106. Shao J, Zheng D, Jiang Z, Xu H, Hu Y, Li X, et al. Curcumin delivery by methoxy polyethylene glycol-poly(caprolactone) nanoparticles inhibits the growth of C6 glioma cells. Acta Biochim Biophys Sin (Shanghai) 2011; 43:267-74; PMID:21349881; http://dx.doi.org/10.1093/abbs/gmr011
107. de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007; 9:412-23; PMID:17622648; http://dx.doi.org/10.1215/15228517-2007-024
108. Jung YD, Ellis LM. Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int J Exp Pathol 2001; 82:309-16; PMID:11846837; http://dx.doi.org/10.1046/j.1365-2613. 2001.00205.x (Pubitemid 34063029)
109. Roskelley CD, Williams DE, McHardy LM, Leong KG, Troussard A, Karsan A, et al. Inhibition of tumor cell invasion and angiogenesis by motuporamines. Cancer Res 2001; 61:6788-94; PMID:11559552 (Pubitemid 32896502)